Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBITDA: 2021-2025

Historic EBITDA for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.8 million.

  • InMed Pharmaceuticals' EBITDA fell 5.77% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 10.88%. This contributed to the annual value of -$7.9 million for FY2025, which is 3.10% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' EBITDA stood at -$1.8 million, which was down 0.71% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year EBITDA high stood at -$472,234 for Q2 2023, and its period low was -$7.9 million during Q2 2022.
  • For the 3-year period, InMed Pharmaceuticals' EBITDA averaged around -$1.8 million, with its median value being -$1.8 million (2024).
  • In the last 5 years, InMed Pharmaceuticals' EBITDA skyrocketed by 94.00% in 2023 and then plummeted by 329.61% in 2024.
  • InMed Pharmaceuticals' EBITDA (Quarterly) stood at -$4.3 million in 2021, then spiked by 50.94% to -$2.1 million in 2022, then increased by 22.39% to -$1.6 million in 2023, then plummeted by 37.47% to -$2.2 million in 2024, then decreased by 5.77% to -$1.8 million in 2025.
  • Its EBITDA was -$1.8 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.1 million in Q1 2025.